ab 17 July 2026 Global Research Analyst matthew.weston@ubs.com +44-20-7567 4055 Global Pharmaceuticals Stranded rebates or M&A opportunity? Our recent report looking at US rebate trends raised a lot of great investor dialogue. One recurring theme of Q&A was a focus on Rebate Walls and how they may influence company strategy in the mid-term. Following the proposed acquisition of Apogee by AbbVie, we were specifically asked which companies have rebates that they can leverage to accelerate in-house pipeline la ...